MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.81
+0.70
+2.25%
After Hours: 31.81 0 0.00% 16:07 11/25 EST
OPEN
31.29
PREV CLOSE
31.11
HIGH
32.21
LOW
30.84
VOLUME
688.30K
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
17.43
MARKET CAP
4.46B
P/E (TTM)
-14.9259
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Allogene Drops After Analyst Review of Drug-Trial Results
Allogene shares were lower after an analyst called the results of an early testing of its multiple-myeloma treatment candidate 'underwhelming.'
TheStreet.com · 11/04 17:44
BIIB, XPEV, CXW and PVAC among midday movers
Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repro Med Systems
Seekingalpha · 11/04 17:40
Biogen, Digirad leads healthcare gainers; Repro Med Systems, Aptevo Therapeutics among major losers
Gainers: Biogen (BIIB) +43%, Digirad (DRAD) +28%, Supernus Pharmaceuticals (SUPN) +21%, Jupiter Wellness (JUPW) +3%, Cassava Sciences (SAVA) +13%.Losers: Repro Med Systems (KRMD) -28%, Aptevo Therapeutics (APVO) -13%, Allogene Therapeutics (ALLO) -13%, Tabula Rasa HealthCare (TRHC) -17%, Aurora Cannabis (ACB) -9%.
Seekingalpha · 11/04 16:01
Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses
Allogene (ALLO) reports no revenues for the third quarter of 2020.
Zacks · 11/04 14:52
Allogene Therapeutics down 17% despite Q3 earnings beat
Allogene Therapeutics ([[ALLO]] -17.1%) Q3 results:Cash, cash equivalents and investments of $1B.Research and development expenses of $51.4M (+28.5% Y/Y), which includes $8.8M of non-cash stock-based compensation expense.Pipeline Highlights: Initiate a three-pronged anti-BCMA
Seekingalpha · 11/04 14:49
Allogene Therapeutics Announces Oral Presentation Of Initial Results From Phase 1 Dose Escalation Study Of ALLO-715 In Relapsed/Refractory Multiple Myeloma On Dec. 5
Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of
Benzinga · 11/04 14:08
Allogene Therapeutics EPS beats by $0.03
Allogene Therapeutics (ALLO): Q3 GAAP EPS of -$0.52 beats by $0.03.Cash, cash equivalents and investments of $1B.Press Release
Seekingalpha · 11/04 12:37
Allogene Therapeutics Q3 EPS $(0.52) Beats $(0.54) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.54) by 3.7 percent. This is a 4 percent decrease over losses of $(0.50) per share from
Benzinga · 11/04 12:33
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALLO. Analyze the recent business situations of Allogene Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALLO stock price target is 51.38 with a high estimate of 70.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 226
Institutional Holdings: 89.68M
% Owned: 63.93%
Shares Outstanding: 140.28M
TypeInstitutionsShares
Increased
56
4.63M
New
66
-966.89K
Decreased
53
5.19M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Executive Director
Arie Belldegrun
President/Chief Executive Officer/Co-Founder/Director
David Chang
Co-Founder/Director
Joshua Kazam
Chief Financial Officer/Primary Contact
Eric Schmidt
Executive Vice President
Rafael Amado
Chief Technology Officer
Alison Moore
Chief Compliance Officer/General Counsel
Veer Bhavnagri
Lead Director/Independent Director
David Bonderman
Independent Director
John DeYoung
Independent Director
Franz Humer
Independent Director
Deborah Messemer
Independent Director
Todd Sisitsky
Independent Director
Owen Witte
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALLO
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Allogene Therapeutics Inc stock information, including NASDAQ:ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALLO stock methods without spending real money on the virtual paper trading platform.